Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
January 09, 2019AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity and Type II diabetes a... 
Printer Friendly Version
January 03, 2019OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
Ion GeneStudio™ S5 Demonstrates Generation of Consistent and Reproducible Results in Lung Cancer Studies ALAMEDA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced its successful transition to the Ion GeneStudio S5 next-generation sequencing (NGS) platform for targeted sequencing. The platform was chosen by OncoCyte after evaluating four leading platforms. OncoCyte... 
Printer Friendly Version
January 02, 2019AgeX Therapeutics to Present at Biotech Showcase 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California. AgeX Founder and CEO Michael D. West, Ph.D., will be speaking at the conference as follows: Date: Wednesday, ... 
Printer Friendly Version